Stock Analysis

Empresas CMPC S.A.'s (SNSE:CMPC) Shareholders Might Be Looking For Exit

It's not a stretch to say that Empresas CMPC S.A.'s (SNSE:CMPC) price-to-earnings (or "P/E") ratio of 7.4x right now seems quite "middle-of-the-road" compared to the market in Chile, where the median P/E ratio is around 8x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/E.

Recent times haven't been advantageous for Empresas CMPC as its earnings have been falling quicker than most other companies. One possibility is that the P/E is moderate because investors think the company's earnings trend will eventually fall in line with most others in the market. You'd much rather the company wasn't bleeding earnings if you still believe in the business. Or at the very least, you'd be hoping it doesn't keep underperforming if your plan is to pick up some stock while it's not in favour.

View our latest analysis for Empresas CMPC

pe-multiple-vs-industry
SNSE:CMPC Price to Earnings Ratio vs Industry January 2nd 2024
Want the full picture on analyst estimates for the company? Then our free report on Empresas CMPC will help you uncover what's on the horizon.

How Is Empresas CMPC's Growth Trending?

The only time you'd be comfortable seeing a P/E like Empresas CMPC's is when the company's growth is tracking the market closely.

Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 25%. At least EPS has managed not to go completely backwards from three years ago in aggregate, thanks to the earlier period of growth. So it appears to us that the company has had a mixed result in terms of growing earnings over that time.

Turning to the outlook, the next three years should bring diminished returns, with earnings decreasing 8.2% per annum as estimated by the nine analysts watching the company. Meanwhile, the broader market is forecast to expand by 21% per year, which paints a poor picture.

In light of this, it's somewhat alarming that Empresas CMPC's P/E sits in line with the majority of other companies. Apparently many investors in the company reject the analyst cohort's pessimism and aren't willing to let go of their stock right now. Only the boldest would assume these prices are sustainable as these declining earnings are likely to weigh on the share price eventually.

What We Can Learn From Empresas CMPC's P/E?

Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

Our examination of Empresas CMPC's analyst forecasts revealed that its outlook for shrinking earnings isn't impacting its P/E as much as we would have predicted. When we see a poor outlook with earnings heading backwards, we suspect share price is at risk of declining, sending the moderate P/E lower. Unless these conditions improve, it's challenging to accept these prices as being reasonable.

Don't forget that there may be other risks. For instance, we've identified 6 warning signs for Empresas CMPC (2 are significant) you should be aware of.

If P/E ratios interest you, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.

Mobile Infrastructure for Defense and Disaster

The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.

Get the investor briefing before the next round of contracts

Sponsored On Behalf of CiTech

Valuation is complex, but we're here to simplify it.

Discover if Empresas CMPC might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SNSE:CMPC

Empresas CMPC

Engages in the production and sale of pulp and wood products in Chile and internationally.

Moderate risk with reasonable growth potential and pays a dividend.

Weekly Picks

WO
MGPI logo
woodworthfund on MGP Ingredients ·

THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Fair Value:US$4034.1% undervalued
22 users have followed this narrative
1 users have commented on this narrative
5 users have liked this narrative
DO
Double_Bubbler
EVTL logo
Double_Bubbler on Vertical Aerospace ·

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

Fair Value:US$6089.9% undervalued
22 users have followed this narrative
3 users have commented on this narrative
17 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8149.0% undervalued
43 users have followed this narrative
4 users have commented on this narrative
8 users have liked this narrative

Updated Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Unicycive Therapeutics (Nasdaq: UNCY) – Preparing for a Second Shot at Bringing a New Kidney Treatment to Market (TEST)

Fair Value:US$21.5370.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KI
RKLB logo
KiwiInvest on Rocket Lab ·

Rocket Lab USA Will Ignite a 30% Revenue Growth Journey

Fair Value:US$97.8335.1% undervalued
137 users have followed this narrative
8 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
120 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3927.7% undervalued
963 users have followed this narrative
6 users have commented on this narrative
25 users have liked this narrative
RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8688.0% undervalued
78 users have followed this narrative
8 users have commented on this narrative
21 users have liked this narrative